



PB 1 of 2013

National Health (Listing of Pharmaceutical Benefits) Amendment Instrument 2013 (No. 1)¹

National Health Act 1953

I, FELICITY McNEILL, First Assistant Secretary, Pharmaceutical Benefits Division, Department of Health and Ageing, delegate of the Minister for Health, make this Instrument under sections 84AF, 84AK, 85, 85A, 88 and 101 of the *National Health Act 1953*.

Dated 8 January 2013

FELICITY McNEILL

First Assistant Secretary
Pharmaceutical Benefits Division
Department of Health and Ageing

1 Name of Instrument

(1) This Instrument is the *National Health (Listing of Pharmaceutical Benefits) Amendment Instrument 2013 (No. 1)*.

(2) This Instrument may also be cited as PB 1 of 2013.

2 Commencement

This Instrument commences on 1 February 2013.

3 Amendment of *National Health (Listing of Pharmaceutical Benefits) Instrument 2012 (PB 71 of 2012)*

Schedule 1 amends the *National Health (Listing of Pharmaceutical Benefits) Instrument 2012 (PB 71 of 2012)*.

Schedule 1 Amendments

[1] Schedule 1, column headed “Determined Quantity”

omit values in all instances where displayed in the column headed “Determined Quantity” for all Listed Drugs, except for:

Methoxyflurane

which retains the value “1” in the column headed “Determined Quantity”

[2] Schedule 1, entry for Alendronic Acid in the form Tablet 70 mg (as alendronate sodium)

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

Fonat	AL	MP NP	C4122 C4123 C4133	4	5	4
-------	----	-------	----------------------	---	---	---

[3] Schedule 1, entry for Atenolol in the form Tablet 50 mg

omit from the column headed “Brand”: **Atenolol generichealth** *substitute:* **Atenolol GH**

[4] Schedule 1, entry for Clopidogrel in the form Tablet 75 mg (as hydrogen sulfate)

omit from the column headed “Responsible Person” for the brand “Iscover”: **BQ** *substitute:* **AV**

[5] Schedule 1, entry for Clopidogrel with aspirin in the form Tablet 75 mg (as hydrogen sulfate)-100 mg

omit from the column headed “Responsible Person” for the brand “DuoCover”: **BQ** *substitute:* **AV**

[6] Schedule 1, entry for Cyproterone in the form Tablet containing cyproterone acetate 50 mg [Max Quantity 20; Number of Repeats 5]

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

Cyproterone Sandoz	HX	MP	C1014 C1230 P1230 C1404	20	5	20
-----------------------	----	----	----------------------------	----	---	----

[7] Schedule 1, entry for Cyproterone in the form Tablet containing cyproterone acetate 50 mg [Max Quantity 100; Number of Repeats 5]

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

Cyproterone Sandoz	HX	MP	C1014 C1230 P1014 P1404 C1404	100	5	50
-----------------------	----	----	----------------------------------	-----	---	----

[8] Schedule 1, entry for Exemestane

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

Exemestane-GA	GM	MP NP	C1541 C2457	30	5	30
---------------	----	-------	-------------	----	---	----

[9] Schedule 1, entry for Fludarabine in the form Solution for I.V. injection 50 mg fludarabine phosphate in 2 mL

insert in the columns in the order indicated, and in alphabetical order for the column headed "Brand":

AS-Fludarabine	YA	MP	C3887	See Note 3	See Note 3	5	PB(100)
----------------	----	----	-------	---------------	---------------	---	---------

[10] Schedule 1, entry for Gabapentin in each of the forms: Capsule 100 mg; Capsule 300 mg; Capsule 400 mg; and Tablet 800 mg

insert in the columns in the order indicated, and in alphabetical order for the column headed "Brand":

Gabapentin Pfizer	FZ	MP NP	C2664	100	5	100	
-------------------	----	-------	-------	-----	---	-----	--

[11] Schedule 1, entry for Gemcitabine in each of the forms: Powder for I.V. infusion 200 mg (as hydrochloride); Powder for I.V. infusion 1 g (as hydrochloride); and Powder for I.V. infusion 2 g (as hydrochloride)

insert in the columns in the order indicated, and in alphabetical order for the column headed "Brand":

AS-Gemcitabine	YA	MP		See Note 3	See Note 3	1	D(100)
----------------	----	----	--	---------------	---------------	---	--------

[12] Schedule 1, entry for Irbesartan in each of the forms: Tablet 75 mg; Tablet 150 mg; and Tablet 300 mg

omit from the column headed "Responsible Person" for the brand "Avapro": **BQ** *substitute:* **AV**

[13] Schedule 1, entry for Irbesartan with Hydrochlorothiazide in the form Tablet 150 mg-12.5 mg

omit from the column headed "Responsible Person" for the brand "Avapro HCT 150/12.5": **BQ** *substitute:* **AV**

[14] Schedule 1, entry for Irbesartan with Hydrochlorothiazide in the form Tablet 300 mg-12.5 mg

omit from the column headed "Responsible Person" for the brand "Avapro HCT 300/12.5": **BQ** *substitute:* **AV**

[15] Schedule 1, entry for Irbesartan with Hydrochlorothiazide in the form Tablet 300 mg-25 mg

omit from the column headed "Responsible Person" for the brand "Avapro HCT 300/25": **BQ** *substitute:* **AV**

[16] Schedule 1, entry for Lercanidipine in each of the forms: Tablet containing lercanidipine hydrochloride 10 mg; and Tablet containing lercanidipine hydrochloride 20 mg

insert in the columns in the order indicated, and in alphabetical order for the column headed "Brand":

Ledip	RA	MP NP		28	5	28	
-------	----	-------	--	----	---	----	--

[17] Schedule 1, entry for Letrozole

insert in the columns in the order indicated, and in alphabetical order for the column headed "Brand":

Pharmacy Choice Letrozole	RI	MP NP	C1608 C2691 C2692	30	5	30	
------------------------------	----	-------	----------------------	----	---	----	--

[18] Schedule 1, entry for Lisinopril in the form Tablet 5 mg

omit:

Prinivil 5	MK	MP NP		30	5	30	
------------	----	-------	--	----	---	----	--

[19] Schedule 1, entry for Metronidazole

omit:

I.V. infusion 500 mg in 100 mL	Injection	Baxter Healthcare Pty Ltd	BX	MP NP	C1300 C1448	10	0	10
				PDP	1448	10	0	10
		DBL Metronidazole Intravenous Infusion	HH	MP NP	C1300 C1448	10	0	10
				PDP	1448	10	0	10

substitute:

I.V. infusion 500 mg in 100 mL	Injection	Baxter Healthcare Pty Ltd	BX	MP NP	C4167 C4168 C4169	10	0	1
				PDP	C4169	10	0	1
		DBL Metronidazole Intravenous Infusion	HH	MP NP	C4167 C4168 C4169	10	0	10
				PDP	C4169	10	0	10
		Metronidazole-Clarix	AE	MP NP	C4167 C4168 C4169	10	0	5
				PDP	C4169	10	0	5

[20] Schedule 1, entry for Nebivolol

omit from the column headed "Responsible Person" (all instances): **CS** *substitute:* **FK**

[21] Schedule 1, entry for Oxaliplatin in each of the forms: Solution concentrate for I.V. infusion 50 mg in 10 mL; Solution concentrate for I.V. infusion 100 mg in 20 mL; and Solution concentrate for I.V. infusion 200 mg in 40 mL

insert in the columns in the order indicated, and in alphabetical order for the column headed "Brand":

AS-Oxaliplatin	YA	MP	C3900 C3901 C3930 C3939	See Note 3	See Note 3	1	D(100)
----------------	----	----	-------------------------	------------	------------	---	--------

[22] Schedule 1, entry for Oxybutynin in the form Transdermal patches 36 mg, 8

omit from the column headed "Responsible Person": **HH** *substitute:* **GM**

[23] Schedule 1, entry for Paclitaxel in each of the forms: Solution concentrate for I.V. infusion 30 mg in 5 mL; Solution concentrate for I.V. infusion 100 mg in 16.7 mL; and Solution concentrate for I.V. infusion 300 mg in 50 mL

insert in the columns in the order indicated, and in alphabetical order for the column headed "Brand":

GN-Paclitaxel	YA	MP	C3186 C3890 C3902 C3917 C3955 C3956	See Note 3	See Note 3	1	D(100)
---------------	----	----	---	---------------	---------------	---	--------

[24] Schedule 1, entry for Pravastatin in the form Tablet containing pravastatin sodium 10 mg [Max Quantity 30; Number of Repeats 5]

omit:

Pravastatin Winthrop	WA	MP	C1540 C3047 P1540	30	5	30
		NP	C1540	30	5	30

[25] Schedule 1, entry for Pravastatin in the form Tablet containing pravastatin sodium 10 mg [Max Quantity 30; Number of Repeats 11]

omit:

Pravastatin Winthrop	WA	MP	C1540 C3047 P3047	30	11	30
-------------------------	----	----	-------------------	----	----	----

[26] Schedule 1, entry for Pravastatin in the form Tablet containing pravastatin sodium 20 mg [Max Quantity 30; Number of Repeats 5]

omit:

Pravastatin Winthrop	WA	MP	C1540 C3047 P1540	30	5	30
		NP	C1540	30	5	30

[27] Schedule 1, entry for Pravastatin in the form Tablet containing pravastatin sodium 20 mg [Max Quantity 30; Number of Repeats 11]

omit:

Pravastatin Winthrop	WA	MP	C1540 C3047 P3047	30	11	30
-------------------------	----	----	-------------------	----	----	----

[28] Schedule 1, entry for Pravastatin in the form Tablet containing pravastatin sodium 40 mg [Max Quantity 30; Number of Repeats 5]

omit:

Pravastatin Winthrop	WA	MP	C1540 C3047 P1540	30	5	30
		NP	C1540	30	5	30

[29] Schedule 1, entry for Pravastatin in the form Tablet containing pravastatin sodium 40 mg [Max Quantity 30; Number of Repeats 11]

omit:

Pravastatin Winthrop	WA	MP	C1540 C3047 P3047	30	11	30
-------------------------	----	----	-------------------	----	----	----

[30] Schedule 1, entry for Simvastatin in the form Tablet 10 mg [Max Quantity 30; Number of Repeats 5]

omit:

Simvastatin Winthrop	WA	MP	C1540 C3047 P1540	30	5	30
		NP	C1540	30	5	30

[31] Schedule 1, entry for Simvastatin in the form Tablet 10 mg [Max Quantity 30; Number of Repeats 11]

omit:

Simvastatin Winthrop	WA	MP	C1540 C3047 P3047	30	11	30
-------------------------	----	----	-------------------	----	----	----

[32] Schedule 1, entry for Simvastatin in the form Tablet 20 mg [Max Quantity 30; Number of Repeats 5]

omit:

Simvastatin Winthrop	WA	MP	C1540 C3047 P1540	30	5	30
		NP	C1540	30	5	30

[33] Schedule 1, entry for Simvastatin in the form Tablet 20 mg [Max Quantity 30; Number of Repeats 11]

omit:

Simvastatin Winthrop	WA	MP	C1540 C3047 P3047	30	11	30
-------------------------	----	----	-------------------	----	----	----

[34] Schedule 1, entry for Simvastatin in the form Tablet 40 mg [Max Quantity 30; Number of Repeats 5]

omit:

Simvastatin Winthrop	WA	MP	C1540 C3047 P1540	30	5	30
		NP	C1540	30	5	30

[35] Schedule 1, entry for Simvastatin in the form Tablet 40 mg [Max Quantity 30; Number of Repeats 11]

omit:

Simvastatin Winthrop	WA	MP	C1540 C3047 P3047	30	11	30
-------------------------	----	----	-------------------	----	----	----

[36] Schedule 1, entry for Simvastatin in the form Tablet 80 mg [Max Quantity 30; Number of Repeats 5]

omit:

Simvastatin Winthrop	WA	MP	C1540 C3047 P1540	30	5	30
		NP	C1540	30	5	30

[37] Schedule 1, entry for Simvastatin in the form Tablet 80 mg [Max Quantity 30; Number of Repeats 11]

omit:

Simvastatin Winthrop	WA	MP	C1540 C3047 P3047	30	11	30
-------------------------	----	----	-------------------	----	----	----

[38] Schedule 1, entry for Sumatriptan in the form Tablet 50 mg (as succinate) for the following brands only:

**APO-Sumatriptan; Chem mart Sumatriptan; Imigran; Sumagran 50; Sumagran Aspen 50; Sumatab;
and Terry White Chemists Sumatriptan**

omit from the column headed "Pack Quantity": **4** *substitute:* **2**

[39] Schedule 1, entry for Testosterone in each of the forms: Transdermal patches 12.2 mg, 60; and Transdermal patches 24.3 mg, 30

omit from the column headed "Responsible Person": **HH** *substitute:* **GM**

[40] Schedule 1, entry for Topotecan

insert in the columns in the order indicated, and in alphabetical order for the column headed "Brand":

Topotecan Agila	YA	MP	C3186	See Note 3	See Note 3	5	D(100)
-----------------	----	----	-------	---------------	---------------	---	--------

[41] Schedule 1, entry for Tramadol in each of the forms: Tablet (sustained release) containing tramadol hydrochloride 100 mg; Tablet (sustained release) containing tramadol hydrochloride 150 mg; and Tablet (sustained release) containing tramadol hydrochloride 200 mg

insert in the columns in the order indicated, and in alphabetical order for the column headed "Brand":

Tramadol SR generichealth	GQ	MP NP	C1537	20	0	20
------------------------------	----	-------	-------	----	---	----

[42] Schedule 1, entry for Tramadol in the form Injection containing tramadol hydrochloride 100 mg in 2 mL

omit from the column headed "Brand": **Tramahexal** *substitute:* **Tramadol Sandoz**

[43] Schedule 1, entry for Vinorelbine in each of the forms: Solution for I.V. infusion 10 mg (as tartrate) in 1 mL; and Solution for I.V. infusion 50 mg (as tartrate) in 5 mL

insert in the columns in the order indicated, and in alphabetical order for the column headed "Brand":

AS-Vinorelbine	YA	MP	C3890 C3907	See Note 3	See Note 3	1	PB(100)
----------------	----	----	-------------	---------------	---------------	---	---------

[44] Schedule 3, details relevant to Responsible person code FK

omit: Invida Australia Pty Ltd *substitute:* A.Menarini Australia Pty Ltd

[45] Schedule 3, after details relevant to Responsible person code XM

insert:

YA	Agila Australasia Pty Ltd	12 154 055 339
----	---------------------------	----------------

[46] Schedule 4, Part 1, entry for Metronidazole

substitute:

Metronidazole		P1416		Treatment of anaerobic infections	
	C4167			Acute anaerobic sepsis Must be treated in a hospital	
	C4168			Prophylaxis to prevent infection Patient must be undergoing large bowel surgery	
	C4169			Acute anaerobic sepsis Must be treated in a hospital	

¹Note

All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the *Legislative Instruments Act 2003*.

See <http://www.comlaw.gov.au>